0000899243-22-010987.txt : 20220314 0000899243-22-010987.hdr.sgml : 20220314 20220314213330 ACCESSION NUMBER: 0000899243-22-010987 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220311 FILED AS OF DATE: 20220314 DATE AS OF CHANGE: 20220314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DEKKERS MARIJN E CENTRAL INDEX KEY: 0001216068 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40097 FILM NUMBER: 22738662 MAIL ADDRESS: STREET 1: GENERAL ELECTRIC COMPANY STREET 2: 41 FARNSWORTH STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ginkgo Bioworks Holdings, Inc. CENTRAL INDEX KEY: 0001830214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 872652913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 27 DRYDOCK AVENUE STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (877) 442-5362 MAIL ADDRESS: STREET 1: 27 DRYDOCK AVENUE STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Soaring Eagle Acquisition Corp. DATE OF NAME CHANGE: 20210210 FORMER COMPANY: FORMER CONFORMED NAME: Spinning Eagle Acquisition Corp. DATE OF NAME CHANGE: 20201027 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-11 0 0001830214 Ginkgo Bioworks Holdings, Inc. DNA 0001216068 DEKKERS MARIJN E C/O GINKGO BIOWORKS HOLDINGS, INC. 27 DRYDOCK AVENUE BOSTON MA 02210 1 0 0 0 Class A Common Stock 2022-03-11 4 A 0 1746706 0.00 A 2121666 D Class A Common Stock 5780364 I By Novalis LifeSciences Investments I, L.P. The reporting person was previously granted awards of restricted stock units covering Class A Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 11, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 1,390,938 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class A Common Stock. The remaining restricted stock units will continue to vest in accordance with the terms of the award. The reporting person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. /s/ Karen Tepichin, Attorney-in-fact 2022-03-14